Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
nSARS-CoV-2, phù phổi và huyết khối: những hiểu biết phân tử có thể từ việc sử dụng các mạch điều chỉnh miRNA-gene
Tóm tắt
Trong bối cảnh tình hình đại dịch toàn cầu do virus Coronavirus 2 gây hội chứng hô hấp cấp tính nặng (nSARS-CoV-2) đã lan rộng, việc nghiên cứu để tái sử dụng thuốc, xác định các mục tiêu thuốc mới và các ứng cử viên vắc-xin đã tạo ra một cuộc chạy đua mới nhằm kiểm soát căn bệnh này. Trong khi chữ ký phân tử của nSARS-CoV-2 vẫn đang được nghiên cứu, tài liệu ngày càng tăng cho thấy sự tương đồng giữa nSARS-CoV-2, phù phổi và rối loạn huyết khối tắc mạch do những đặc điểm triệu chứng chung. Một phương pháp y học mạng được sử dụng để khám phá sự phức tạp phân tử của bệnh và để hé lộ các quỹ đạo phân tử chung của phù và huyết khối liên quan đến nSARS-CoV-2. Một mạng lưới điều chỉnh miRNA nhạy cảm với nSARS-CoV-2: yếu tố phiên mã (TF): gene đã được xây dựng, và các mạch điều chỉnh ba phần liên quan đến miRNA nhạy cảm với vật chủ đã được xác định. Các mạch điều chỉnh này kiểm soát các con đường tín hiệu như quá trình nội bào virus, tái bản virus, phản ứng viêm, tạo mạch phổi, kiểm soát vòng đời tế bào, ổn định protein gai virus, và trình bày kháng nguyên, v.v. Một mạch điều chỉnh miRNA-gene độc đáo chứa một tập hợp gồm bốn mô típ FFL trung tâm được đề xuất nhằm điều chỉnh các con đường tín hiệu nội bào virus và trình bày kháng nguyên. Những mạch điều chỉnh này cũng gợi ý về những tương quan/ tương đồng tiềm ẩn trong các cơ chế phân tử trong quá trình nhiễm nSARS-CoV-2, các bệnh phổi và rối loạn huyết khối tắc mạch, do đó có thể mở ra con đường để tái sử dụng các loại thuốc. Một số miRNA và gene quan trọng cũng đã được đề xuất làm các dấu ấn ứng cử viên tiềm năng. Một bức tranh phân tử chi tiết về tín hiệu TGF như là con đường chung, có thể đóng vai trò quan trọng trong việc kiểm soát những bệnh lý sinh lý chung giữa các bệnh, cũng đã được đưa ra.
Từ khóa
#nSARS-CoV-2 #phù phổi #huyết khối #mạch điều chỉnh miRNA-gene #mạng lưới điều chỉnhTài liệu tham khảo
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):69.
Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3′ and 5′ ends. Virus Res. 2015;206:120–33.
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678–85.
Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2020;S1684-1182(20):30082–7.
Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
Zhang H, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
Hu Y, et al. The M protein of SARS-CoV: basic structural and immunological properties. Genomics Proteomics Bioinformatics. 2003;1(2):118–30.
McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991–3018.
Rahila Sardar DS, Birla S, Gupta D. Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis. bioRxiv. 2020;2020.03.21.001586. https://doi.org/10.1101/2020.03.21.001586.
Müşerref Duygu Saçar Demirci AA. Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection. BioRxiv. 2020;2020.03.15.992438. https://doi.org/10.1101/2020.03.15.992438.
Martinez NJ, Walhout AJ. The interplay between transcription factors and microRNAs in genome-scale regulatory networks. Bioessays. 2009;31(4):435–45.
Lin Y, et al. MiRNA and TF co-regulatory network analysis for the pathology and recurrence of myocardial infarction. Sci Rep. 2015;5:9653.
Gupta A, et al. Role of miRNAs in hypoxia-related disorders. J Biosci. 2018;43(4):739–49.
Li R, et al. CMTCN: a web tool for investigating cancer-specific microRNA and transcription factor co-regulatory networks. PeerJ. 2018;6:e5951.
Mangan S, Alon U. Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci U S A. 2003;100(21):11980–5.
Hsieh WT, et al. Transcription factor and microRNA-regulated network motifs for cancer and signal transduction networks. BMC Syst Biol. 2015;9(Suppl 1):S5.
Wang L, et al. Identifying functions and prognostic biomarkers of network motifs marked by diverse chromatin states in human cell lines. Oncogene. 2020;39(3):677–89.
Solaimanzadeh I. Acetazolamide, Nifedipine and Phosphodiesterase inhibitors: rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (COVID-19). Cureus. 2020;12(3):e7343.
Han H, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116–20.
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.
Bing He, LG. Prediction of repurposed drugs for treating lung injury in COVID-19. arXiv [q‐bio.TO]. 2020;9:609.
Sengupta D, Bandyopadhyay S. Participation of microRNAs in human interactome: extraction of microRNA-microRNA regulations. Mol BioSyst. 2011;7(6):1966–73.
Ru Y, et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42(17):e133.
Chawla K, et al. TFcheckpoint: a curated compendium of specific DNA-binding RNA polymerase II transcription factors. Bioinformatics. 2013;29(19):2519–20.
Kummerfeld SK, Teichmann SA. DBD: a transcription factor prediction database. Nucleic Acids Res. 2006;34(Database issue):D74–81.
Lamesch P, et al. hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics. 2007;89(3):307–15.
Schaefer U, Schmeier S, Bajic VB. TcoF-DB: dragon database for human transcription co-factors and transcription factor interacting proteins. Nucleic Acids Res. 2011;39(Database issue):D106–10.
Fulton DL, et al. TFCat: the curated catalog of mouse and human transcription factors. Genome Biol. 2009;10(3):R29.
Wingender E, et al. TFClass: expanding the classification of human transcription factors to their mammalian orthologs. Nucleic Acids Res. 2018;46(D1):D343–7.
Matys V, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31(1):374–8.
Lesurf R, et al. ORegAnno 3.0: a community-driven resource for curated regulatory annotation. Nucleic Acids Res. 2016;44(D1):D126–32.
Han H, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–6.
Tong Z, et al. TransmiR v2.0: an updated transcription factor-microRNA regulation database. Nucleic Acids Res. 2019;47(D1):D253–8.
Bandyopadhyay S, Bhattacharyya M. PuTmiR: a database for extracting neighboring transcription factors of human microRNAs. BMC Bioinformatics. 2010;11:190.
Croft D, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011;39(Database issue):D691–7.
Iorio F, et al. Efficient randomization of biological networks while preserving functional characterization of individual nodes. BMC Bioinformatics. 2016;17(1):542.
Yang N, Shen HM. Targeting the Endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16(10):1724–31.
Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF. Human leukocyte antigen susceptibility map for SARS-CoV-2. J Virol. 2020;94(13):e00510–20.
Yan Z, et al. Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res. 2012;40(17):e135.
Shen-Orr SS, et al. Network motifs in the transcriptional regulation network of Escherichia coli. Nat Genet. 2002;31(1):64–8.
Chen LZ, Lung L. Adenocarcinoma Patients Own Higher Risk of SARS-CoV-2 Infection. Preprint. 2020;2020020386.
Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, Aziz B. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol. 2020;92:1580–6.
Leon-Icaza SA, Zeng M, Rosas-Taraco AG. microRNAs in viral acute respiratory infections: immune regulation, biomarkers, therapy, and vaccines. ExRNA. 2019;1(1):1.
Wei J, et al. Recent advances in the discovery of HIF-1alpha-p300/CBP inhibitors as anti-Cancer agents. Mini-Rev Med Chem. 2018;18(4):296–309.
Fish JE, et al. Dynamic regulation of VEGF-inducible genes by an ERK/ERG/p300 transcriptional network. Development. 2017;144(13):2428–44.
Kumar A, et al. MicroRNA hsa-miR-324-5p Suppresses H5N1 Virus Replication by Targeting the Viral PB1 and Host CUEDC2. J Virol. 2018;92(19):e01057-18.
McMahon SB. MYC and the control of apoptosis. Cold Spring Harb Perspect Med. 2014;4(7):a014407.
Bretones G, Delgado MD, Leon J. Myc and cell cycle control. Biochim Biophys Acta. 2015;1849(5):506–16.
Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A. 2008;105(18):6584–9.
Peltenburg LT, Schrier PI. Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements. Immunogenetics. 1994;40(1):54–61.
Fukushi M, et al. Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus. J Virol. 2012;86(21):11745–53.
Li SW, et al. SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-beta1 via ROS/p38 MAPK/STAT3 pathway. Sci Rep. 2016;6:25754.
Surjit M, et al. The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells. J Biol Chem. 2006;281(16):10669–81.
Li Y, et al. The roles of exosomal miRNAs and lncRNAs in lung diseases. Signal Transduct Target Ther. 2019;4:47.
Chen G, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9.
Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.
Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
Zhang Z, et al. Clinical presentation of hemophagocytic lymphohistiocytosis in adults is less typical than in children. Clinics (Sao Paulo). 2016;71(4):205–9.
Oudkerk M, et al. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Radiology. 2020;297(1):E216–22.
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7.
Li MO, Flavell R., Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity, 2008. 28(4): p. 468–476.
Li MO, Flavell R. TGF-beta: a master of all T cell trades. Cell. 2008;134(3):392–404.
Li MO, Wan Y, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99–146.
Chen W. A potential treatment of COVID-19 with TGF-β blockade. Int J Biol Sci. 2020;16(11):1954–5.
Tobinick E. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr Med Res Opin. 2004;20(1):39–40.
Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M. Duncan Richards,Tracy Hussell, Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet J. 2020;395(10234):1407–9.
Guan WJ, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a Nationwide analysis. Eur Respir J. 2020.
Liyang Li, Qihong H, Wang DC, Ingbar DH, Wang A. Acute lung injury in patients with COVID-19 infection. Clin Transl Med. 2020;10:20–7.
Luks AM, Freer L, Grissom CK, McIntosh SE, Schoene RB, Swenson ER, Hackett PH. COVID-19 Lung Injury is Not High Altitude Pulmonary Edema. High Alt Med Biol. 2020:1–2.
Jin T, et al. Association between the IL1R2 rs2072472 polymorphism and high-altitude pulmonary edema risk. Mol Genet Genomic Med. 2019;7(3):e542.
Sharma M, Singh SB, Sarkar S. Genome wide expression analysis suggests perturbation of vascular homeostasis during high altitude pulmonary edema. PLoS One. 2014;9(1):e85902.
Kubo K, et al. Inflammatory cytokines in BAL fluid and pulmonary hemodynamics in high-altitude pulmonary edema. Respir Physiol. 1998;111(3):301–10.
Alam P, Saini N, Pasha MA. MicroRNAs: an apparent switch for high-altitude pulmonary edema. Microrna. 2015;4(3):158–67.
Jiang F, et al. MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. Int J Oncol. 2019;54(1):128–38.
Li G, et al. MiR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFBR2. Biomed Pharmacother. 2017;96:1170–8.
Gaddam RR, Chambers S, Bhatia M. ACE and ACE2 in inflammation: a tale of two enzymes. Inflamm Allergy Drug Targets. 2014;13(4):224–34.
Infante M, et al. Differential diagnosis and management of focal ground-glass opacities. Eur Respir J. 2009;33(4):821–7.
Zompatori M, Rimondi MR. Diffuse ground-glass opacity of the lung. A guide to interpreting the high-resolution computed tomographic (HRCT) picture. Radiol Med. 1994;88(5):576–81.
Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest. 2004;125(2):754–65.
Green DR, Llambi F. Cell Death Signaling. Cold Spring Harb Perspect Biol. 2015;7(12):1–25.
He Y, et al. miR-149 in human Cancer: a systemic review. J Cancer. 2018;9(2):375–88.
Jiang L, et al. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res. 2011;37(7):387–98.
Rukov JL, et al. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform. 2014;15(4):648–59.
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220(1):1–13.
Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123(17):2605–13.
Lee N, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–94.
Chong PY, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med. 2004;128(2):195–204.
Matsuo T, et al. Fibrin D-dimer in thrombogenic disorders. Semin Thromb Hemost. 2000;26(1):101–7.
Welty-Wolf KE, et al. Coagulation and inflammation in acute lung injury. Thromb Haemost. 2002;88(1):17–25.
Idell S, et al. Mechanisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-beta and TNF-alpha. Am J Phys. 1992;263(4 Pt 1):L487–94.
Jablonska E, et al. Transforming growth factor-beta1 induces expression of human coagulation factor XII via Smad3 and JNK signaling pathways in human lung fibroblasts. J Biol Chem. 2010;285(15):11638–51.
Zhao X, Nicholls JM, Chen YG. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J Biol Chem. 2008;283(6):3272–80.
Grimson A, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27(1):91–105.
Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol. 2001;115(1):3–12.